89Zr-labeled NY008 PET Imaging in Patients
Multiple Myeloma
About this trial
This is an interventional diagnostic trial for Multiple Myeloma
Eligibility Criteria
Inclusion Criteria: Older than 18 years old, male or female; Patients diagnosed with relapsing or refractory multiple myeloma; LVEF≥50%; ECOG score 0~2; Exclusion Criteria: Life expectancy of less than 3 months; Participated in other clinical research within 1 month; Recovery from major trauma (including surgery) within 28 days prior to study treatment; Patients with systemic or locally severe infections, or other serious coexisting diseases; Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines; Patients with autoimmune diseases, including rheumatoid arthritis; Inadequate control of arrhythmias, including atrial fibrillation; Uncontrolled hypertension; Patients with allergies or allergies to any component of the imaging agent or antibody; Patients who cannot undergo PET/CT imaging scan; Syphilis, HBV, HCV, or HIV positive subjects; Male and female subjects of reproductive age cannot take effective contraceptive measures; Pregnant or lactating women; Patients with a history of mental illness or related conditions; Other subjects considered unsuitable by researchers.
Sites / Locations
- Affiliated Hospital of Jiangnan UniversityRecruiting
Arms of the Study
Arm 1
Experimental
89Zr-NY008